ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...

With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...

DelveInsight's "TEPMETKO Market Size, Forecast, and Market Insight Report" highlights the details around TEPMETKO, a kinase ...

H.C. Wainwright analyst Andres Maldonado initiated coverage of ImmunityBio (IBRX) with a Buy rating and $8 price target ImmunityBio is a ...

FY 2024 revenue of $228.4 million, in-line with company guidance Commercial Cell & Gene Therapy revenue rose to $26 million in FY 2024, up 20% year-over-year Supporting ...

FY 2024 revenue of $228.4 million, in-line with company guidance <li /> Commercial Cell & Gene Therapy revenue rose to $26 million in FY ...

We recently published an article titled Trade Tensions Weigh Heavily on 10 Stocks. In this article, we are going to take a ...

ImmunityBio’s revenue growth was driven by sales of its ANKTIVA therapy following FDA approval in April 2024. The company reported net product revenue of $7.2 million for Q4, representing a 21% ...

New positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored Phase III OUtMATCH study, ...

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for Anktiva ...

Its partnership with Novartis focuses on developing ociperlimab, a TIGIT inhibitor, while a Phase 3 trial with ImmunityBio ...